Ergomed plc Board Change (1702C)
June 17 2021 - 1:05AM
UK Regulatory
TIDMERGO
RNS Number : 1702C
Ergomed plc
17 June 2021
PRESS RELEASE
Board Change
Guildford, UK - 17 June 2021: Ergomed plc (LSE: ERGO) ('Ergomed'
or the 'Company'), a company focused on providing specialised
services to the pharmaceutical industry, today announces that Rolf
Soderstrom has informed the Board of his intention to step down
from the Board to focus on his other business activities, in
particular his executive role as Chief Financial Officer of Syncona
Investment Management Limited. Mr Soderstrom will remain on the
Board until 30 September 2021 to provide a period of
transition.
Dr Miroslav Reljanović, Executive Chairman of Ergomed,
commented: "Rolf has brought tremendous value to the Ergomed Board
since joining in 2019 and made a significant contribution to the
growth and success we have shown during the recent period. On
behalf of the Board, I would like to thank him for his considerable
input and wish him well in all his future endeavours."
Rolf Soderstrom said: "It has been a pleasure to play a part in
Ergomed's success since its strategic transition to a fully
services-based business model. Its continued strong growth, track
record of effective M&A and the quality of the management team
and Board mean it is exceptionally well positioned to deliver on
its vision of global leadership in specialised pharmaceutical
services addressing unmet medical needs and patient safety."
ENDS
Enquiries:
Ergomed plc Tel: +44 (0) 1483 402
975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Matthew O'Dowd (Nominated
Adviser)
James Black (Broker)
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand and a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO). For further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASFMEEMEFSEEM
(END) Dow Jones Newswires
June 17, 2021 02:05 ET (06:05 GMT)
Ergomed (LSE:ERGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2023 to Apr 2024